SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
SEC Accession No. 0001144204-16-080033
Filing Date
2016-02-09
Accepted
2016-02-09 16:57:47
Documents
11
Period of Report
2016-02-09

Document Format Files

Seq Description Document Type Size
1 FORM 6-K v430769_6k.htm 6-K 11145
2 PRESS RELEASE DATED FEBRUARY 9, 2016 v430769_ex99-1.htm EX-99.1 60117
3 MANAGEMENTS DISCUSSION AND ANALYSIS v430769_ex99-2.htm EX-99.2 121087
4 CONSOLIDATED FINANCIAL STATEMENTS v430769_ex99-3.htm EX-99.3 343095
5 CERTIFICATION OF INTERIM FILINGS SIGNED BY THE CHIEF EXECUTIVE OFFICER v430769_ex99-4.htm EX-99.4 12154
6 CERTIFICATION OF INTERIM FILINGS SIGNED BY THE CHIEF FINANCIAL OFFICER v430769_ex99-5.htm EX-99.5 12173
7 LETTER TO SHAREHOLDERS v430769_ex99-6.htm EX-99.6 14721
8 GRAPHIC tex99-1logo.jpg GRAPHIC 14910
9 GRAPHIC tex99-2logo.jpg GRAPHIC 35704
10 GRAPHIC tex99-3sig1.jpg GRAPHIC 3272
11 GRAPHIC tex99-3sig2.jpg GRAPHIC 5768
  Complete submission text file 0001144204-16-080033.txt   658207
Mailing Address 101 COLLEGE STREET SUITE 220 TORONTO A6 M5G 1L7
Business Address 101 COLLEGE STREET SUITE 220 TORONTO A6 M5G 1L7 416-260-7770
Transition Therapeutics Inc. (Filer) CIK: 0001399250 (see all company filings)

IRS No.: 000000000 | Fiscal Year End: 0630
Type: 6-K | Act: 34 | File No.: 001-33514 | Film No.: 161400737
SIC: 2833 Medicinal Chemicals & Botanical Products